Cargando…

Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?

Introduction: Retroperitoneal fibrosis is a rare disease. It can be primary (Ormond’s disease) or secondary to inflammation, malignancy or some drugs. Beta-adrenergic blockers including propranolol can cause the retroperitoneal fibrosis disease. Case: A 44-year-old woman who was taking propranolol f...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirani, Majid, Davoudian, Azadeh, Sharifi, Abolghasem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nickan Research Institute 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206015/
https://www.ncbi.nlm.nih.gov/pubmed/25340131
http://dx.doi.org/10.12861/jrip.2013.22
_version_ 1782340754070306816
author Shirani, Majid
Davoudian, Azadeh
Sharifi, Abolghasem
author_facet Shirani, Majid
Davoudian, Azadeh
Sharifi, Abolghasem
author_sort Shirani, Majid
collection PubMed
description Introduction: Retroperitoneal fibrosis is a rare disease. It can be primary (Ormond’s disease) or secondary to inflammation, malignancy or some drugs. Beta-adrenergic blockers including propranolol can cause the retroperitoneal fibrosis disease. Case: A 44-year-old woman who was taking propranolol for 13 years came to our center with complaints of oliguria and uremia symptoms (malaise, nausea and vomiting). After some investigations, it was found that the disease was retroperitoneal fibrosis. In the first step, she was treated with corticosteroids and then because of inadequate response, bilateral ureterolysis was performed. Then, an additional course of corticosteroid therapy was required after surgery. Conclusion: Retroperitoneal fibrosis is an unknown cause disease that can involve ureters and can cause obstructive symptoms. The imaging procedure of choice for diagnosis is abdominal CT scanning with oral and intravenous contrast agents. Corticosteroids are the first option for treatment, however, if they are not effective and in case of severe obstruction, ureterolysis can be performed. Beta- adrenergic blocker drugs that are widely used in heart diseases can be a cause of retroperitoneal fibrosis.
format Online
Article
Text
id pubmed-4206015
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nickan Research Institute
record_format MEDLINE/PubMed
spelling pubmed-42060152014-10-22 Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis? Shirani, Majid Davoudian, Azadeh Sharifi, Abolghasem J Renal Inj Prev Case Report Introduction: Retroperitoneal fibrosis is a rare disease. It can be primary (Ormond’s disease) or secondary to inflammation, malignancy or some drugs. Beta-adrenergic blockers including propranolol can cause the retroperitoneal fibrosis disease. Case: A 44-year-old woman who was taking propranolol for 13 years came to our center with complaints of oliguria and uremia symptoms (malaise, nausea and vomiting). After some investigations, it was found that the disease was retroperitoneal fibrosis. In the first step, she was treated with corticosteroids and then because of inadequate response, bilateral ureterolysis was performed. Then, an additional course of corticosteroid therapy was required after surgery. Conclusion: Retroperitoneal fibrosis is an unknown cause disease that can involve ureters and can cause obstructive symptoms. The imaging procedure of choice for diagnosis is abdominal CT scanning with oral and intravenous contrast agents. Corticosteroids are the first option for treatment, however, if they are not effective and in case of severe obstruction, ureterolysis can be performed. Beta- adrenergic blocker drugs that are widely used in heart diseases can be a cause of retroperitoneal fibrosis. Nickan Research Institute 2013-06-01 /pmc/articles/PMC4206015/ /pubmed/25340131 http://dx.doi.org/10.12861/jrip.2013.22 Text en Copyright © 2013 The Author(s); Published by Nickan Research Institute http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Shirani, Majid
Davoudian, Azadeh
Sharifi, Abolghasem
Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
title Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
title_full Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
title_fullStr Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
title_full_unstemmed Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
title_short Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
title_sort retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206015/
https://www.ncbi.nlm.nih.gov/pubmed/25340131
http://dx.doi.org/10.12861/jrip.2013.22
work_keys_str_mv AT shiranimajid retroperitonealfibrosisassociatedwithpropranololacasereportiscorticosteroidadministrationnecessaryafterureterolysis
AT davoudianazadeh retroperitonealfibrosisassociatedwithpropranololacasereportiscorticosteroidadministrationnecessaryafterureterolysis
AT sharifiabolghasem retroperitonealfibrosisassociatedwithpropranololacasereportiscorticosteroidadministrationnecessaryafterureterolysis